Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Arcutis Biotherapeutics, Inc. ARQT

Set alert

Price alert · ARQT

All alert types
31.26 USD -0.81 -2.53%

At close · Nov 2

31.00 -0.26 -0.83%

After hours · Nov 2, 4:00 PM ET

Bid
31.24 × 2
Ask
31.26 × 2
31.20 Day range 32.24
19.30 52-week range 33.30
YTD
+7.64%
1 year
+23.51%
Open
32.07
Prev close
32.07
Mkt cap
3.93B
Vol
1.51M
Avg vol
2.51M
EPS
0.22
P/E
142.09
Div yield
0.00%
More statistics
Low
31.20
High
32.24
Forward P/E
23.34
Beta
1.63
Short ratio
6.13
Inst. own
108.57%
Dividend
0.00
Ex-div date
Earnings
Nov 4, 2026
50-d avg
26.66
200-d avg
25.25
1y target
39.13

1D chart

Chart tools
Interval
1m5m15m30m

Signals (66)
NameTimeAgo
RSI: Oversold3:56 PM14 hours ago
MACD: Sell Signal3:54 PM15 hours ago
MACD: Buy Signal3:41 PM15 hours ago
RSI: Oversold3:35 PM15 hours ago
RSI: Oversold3:32 PM15 hours ago
RSI: Oversold3:25 PM15 hours ago
RSI: Oversold3:22 PM15 hours ago
SMA: Bearish3:19 PM15 hours ago
MACD: Sell Signal3:10 PM15 hours ago
RSI: Overbought3:01 PM15 hours ago
MACD: Buy Signal2:53 PM16 hours ago
SMA: Bullish2:51 PM16 hours ago
SMA: Bullish2:51 PM16 hours ago
SMA: Bearish2:50 PM16 hours ago
SMA: Bearish2:50 PM16 hours ago
MACD: Sell Signal2:50 PM16 hours ago
SMA: Bullish2:44 PM16 hours ago
SMA: Bearish2:40 PM16 hours ago
SMA: Bullish2:38 PM16 hours ago
SMA: Bearish2:36 PM16 hours ago

Newest 20 of 66.

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 39.13 +25.2% upside
Target (low)
34.00
Target (mean)
39.13
Target (high)
48.00
Ratings (0m) 8 7 buy · 1 hold · 0 sell
  • Strong buy2
  • Buy5
  • Hold1
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 8
  • 1 month ago 7
  • 2 months ago 8

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

ARQT analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter0.168330.10 – 0.200.06+180.6%142.59M+43.7%6
Next quarter0.231670.03 – 0.390.13+78.2%160.67M+24.1%6
Current year0.4250.20 – 0.62-0.13+426.9%538.56M+43.2%6
Next year1.340.80 – 2.080.425+214.9%695.69M+29.2%6

Upgrades and downgrades

The latest rating changes

ARQT analyst upgrades and downgrades
DateFirmActionFromTo
Oct 19, 2026GuggenheimMaintainedBuyBuy
Oct 15, 2026Cantor FitzgeraldInitiated—Overweight
Aug 6, 2026Morgan StanleyMaintainedOverweightOverweight
Aug 6, 2026GuggenheimMaintainedBuyBuy
Aug 6, 2026NeedhamMaintainedBuyBuy
May 7, 2026NeedhamReiteratedBuyBuy
Mar 2, 2026MizuhoMaintainedOutperformOutperform
Feb 27, 2026GuggenheimMaintainedBuyBuy
Feb 26, 2026TD CowenMaintainedBuyBuy
Feb 26, 2026HC Wainwright & Co.MaintainedBuyBuy
Feb 26, 2026NeedhamMaintainedBuyBuy
Jan 26, 2026NeedhamMaintainedBuyBuy
Nov 28, 2025MizuhoMaintainedOutperformOutperform
Oct 30, 2025Goldman SachsMaintainedNeutralNeutral
Oct 28, 2025NeedhamMaintainedBuyBuy
Aug 7, 2025NeedhamMaintainedBuyBuy
Jul 25, 2025Goldman SachsInitiated—Neutral
May 23, 2025NeedhamReiteratedBuyBuy
Apr 9, 2025NeedhamReiteratedBuyBuy
Apr 3, 2025GuggenheimReiteratedBuyBuy
Apr 3, 2025HC Wainwright & Co.ReiteratedBuyBuy
Apr 3, 2025NeedhamReiteratedBuyBuy
Mar 11, 2025JefferiesMaintainedBuyBuy
Feb 27, 2025Goldman SachsMaintainedNeutralNeutral
Feb 26, 2025HC Wainwright & Co.ReiteratedBuyBuy
Feb 26, 2025MizuhoMaintainedOutperformOutperform
Feb 26, 2025NeedhamReiteratedBuyBuy
Feb 24, 2025GuggenheimReiteratedBuyBuy
Feb 10, 2025GuggenheimReiteratedBuyBuy
Jan 13, 2025HC Wainwright & Co.ReiteratedBuyBuy